ストックスクリーナーアプリを入手
14.78
4.34%
-0.67
アフターアワーズ：
14.95
0.17
+1.15%
前日終値:
$15.45
開ける：
$15.51
24時間の取引高:
3.47M
Relative Volume:
1.53
時価総額：
$1.27B
収益：
$139.71M
当期純損益:
$-209.36M
株価収益率:
-4.9932
EPS:
-2.96
ネットキャッシュフロー:
$-160.60M
1週間 パフォーマンス:
-4.95%
1か月 パフォーマンス:
-3.99%
6か月 パフォーマンス:
+12.65%
1年 パフォーマンス:
-20.67%
1日の値動き範囲:
$14.61
$15.77
1週間の範囲:
$14.61
$15.94
52週間の値動き範囲:
$8.58
$22.50
Syndax Pharmaceuticals Inc Stock (SNDX) Company Profile
名前
Syndax Pharmaceuticals Inc
セクター
電話
781-419-1400
住所
730 THIRD AVENUE, NEW YORK, MA
SNDX を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SNDX
Syndax Pharmaceuticals Inc
|
14.78 | 1.33B | 139.71M | -209.36M | -160.60M | -2.96 |
|
VRTX
Vertex Pharmaceuticals Inc
|
383.12 | 99.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
591.99 | 63.46B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
453.56 | 59.27B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
736.76 | 44.78B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
334.40 | 37.75B | 3.81B | -644.79M | -669.77M | -6.24 |
Syndax Pharmaceuticals Inc Stock (SNDX) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2025-09-10 | 再開されました | Stifel | Buy |
| 2025-09-04 | 再開されました | Guggenheim | Buy |
| 2025-08-05 | 繰り返されました | BTIG Research | Buy |
| 2025-07-10 | 開始されました | Goldman | Buy |
| 2024-10-24 | 開始されました | UBS | Buy |
| 2024-06-28 | 開始されました | Jefferies | Buy |
| 2024-01-31 | ダウングレード | Scotiabank | Sector Outperform → Sector Perform |
| 2023-12-22 | 開始されました | Mizuho | Buy |
| 2023-10-25 | 開始されました | BofA Securities | Buy |
| 2023-10-11 | 開始されました | Goldman | Buy |
| 2023-07-27 | 開始されました | Scotiabank | Sector Outperform |
| 2023-07-11 | 開始されました | Guggenheim | Buy |
| 2023-04-17 | 再開されました | BTIG Research | Buy |
| 2023-01-31 | 開始されました | Stifel | Buy |
| 2023-01-03 | 開始されました | JP Morgan | Overweight |
| 2022-07-28 | 再開されました | B. Riley Securities | Buy |
| 2022-04-11 | 開始されました | H.C. Wainwright | Buy |
| 2022-02-15 | 開始されました | Goldman | Buy |
| 2021-06-04 | 再開されました | Robert W. Baird | Outperform |
| 2021-05-25 | 開始されました | Citigroup | Buy |
| 2021-02-18 | 開始されました | B. Riley Securities | Buy |
| 2020-12-03 | 開始されました | Stifel | Buy |
| 2020-05-22 | アップグレード | Citigroup | Neutral → Buy |
| 2020-05-22 | ダウングレード | H.C. Wainwright | Buy → Neutral |
| 2020-05-18 | ダウングレード | Citigroup | Buy → Neutral |
| 2020-05-11 | 繰り返されました | H.C. Wainwright | Buy |
| 2020-03-04 | 開始されました | Barclays | Overweight |
| 2020-01-13 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-03-08 | 繰り返されました | H.C. Wainwright | Buy |
| 2019-01-04 | 開始されました | Robert W. Baird | Outperform |
| 2018-01-05 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-03-16 | 開始されました | FBR & Co. | Outperform |
| 2017-03-02 | 開始されました | Instinet | Buy |
| 2016-10-07 | 開始されました | Guggenheim | Buy |
| 2016-03-28 | 開始されました | Citigroup | Buy |
| 2016-03-28 | 開始されました | JMP Securities | Mkt Outperform |
| 2016-03-28 | 開始されました | Morgan Stanley | Overweight |
すべてを表示
Syndax Pharmaceuticals Inc (SNDX) 最新ニュース
Syndax Pharmaceuticals (NASDAQ:SNDX) Given "Buy" Rating at BTIG Research - MarketBeat
Highs Report: What’s next for IRIDEX Corporation stockBreakout Watch & Daily Profit Focused Stock Screening - khodrobank.com
Update Recap: Can CZWI disrupt its industryEarnings Recap Report & Verified Entry Point Signals - khodrobank.com
BTIG Reiterates Buy Rating on SNDX with $56 Price Target | SNDX Stock News - GuruFocus
3 Potential Biotech Acquisition Targets - Seeking Alpha
SNDX: Revumenib Gains Key NCCN Recommendation for AML Treatment - GuruFocus
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for the Treatment of Relapsed or Refractory NPM1 Mutated Acute Myeloid Leukemia - The Manila Times
Syndax’s Revuforj® (revumenib) Included in NCCN Clinical - GlobeNewswire
Major Treatment Update: Syndax's Revuforj Secures NCCN Recognition for Rare Leukemia Mutation Therapy - Stock Titan
Breakouts Watch: Does Syndax Pharmaceuticals Inc. have strong fundamentalsPortfolio Value Report & Expert Curated Trade Ideas - khodrobank.com
Syndax resumed with Buy at Stifel on newly launched drugs - MSN
Syndax Pharmaceuticals’ SWOT analysis: biotech stock navigates AML market By Investing.com - Investing.com Canada
Syndax Pharmaceuticals (NASDAQ:SNDX) Stock Price Down 4.8%Time to Sell? - MarketBeat
Syndax Pharmaceuticals’ SWOT analysis: biotech stock navigates AML market - Investing.com
Risk Hedge: Is Syndax Pharmaceuticals Inc stock a top performer YTDJuly 2025 Technicals & Stepwise Swing Trade Plans - خودرو بانک
Fundamentals Check: Can L3Harris Technologies Inc deliver consistent EPS growthWeekly Risk Summary & Stock Portfolio Risk Control - خودرو بانک
Earnings Recap: What are the future prospects of Syndax Pharmaceuticals IncTrade Analysis Report & Real-Time Market Sentiment Alerts - khodrobank.com
Syndax Pharmaceuticals (NASDAQ:SNDX) Now Covered by Stifel Nicolaus - MarketBeat
Exome Asset Management LLC Increases Stake in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
213,159 Shares in Syndax Pharmaceuticals, Inc. $SNDX Acquired by Zimmer Partners LP - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) CEO Sells $2,581,407.87 in Stock - MarketBeat
Polar Asset Management Partners Inc. Has $1.31 Million Holdings in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals, Inc. $SNDX Shares Bought by Parkman Healthcare Partners LLC - MarketBeat
Syndax Pharmaceuticals: Revumenib PDUFA Review mNPM1 AML And Move Towards MSS CRC (SNDX) - Seeking Alpha
SNDX: Stifel Reinstates 'Buy' Rating with $44 Price Target | SND - GuruFocus
Syndax (SNDX) Gains "Buy" Rating from Stifel, Eyeing Major Growt - GuruFocus
Stifel Initiates Syndax Pharmaceuticals(SNDX.US) With Buy Rating, Announces Target Price $44 - 富途牛牛
Stifel resumes Syndax Pharmaceuticals stock coverage with Buy rating By Investing.com - Investing.com Canada
Syndax Pharmaceuticals, Inc. $SNDX Shares Sold by Granahan Investment Management LLC - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Now Covered by Guggenheim - MarketBeat
Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Receives Consensus Rating of "Buy" from Brokerages - MarketBeat
Fibonacci Retracement Aligns with Support in Syndax Pharmaceuticals Inc.Options Play & Risk Managed Investment Signals - beatles.ru
Ieq Capital LLC Invests $727,000 in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals at H.C. Wainwright: Strategic Growth and Profitability By Investing.com - Investing.com Canada
Is Syndax Pharmaceuticals Inc. stock a value trapQuarterly Portfolio Report & Free Daily Entry Point Trade Alerts - beatles.ru
Invesco Ltd. Has $944,000 Stake in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Syndax Pharmaceuticals (NASDAQ:SNDX) Price Target Raised to $24.00 - Defense World
Is Syndax Pharmaceuticals Inc. stock forming a triangle patternLayoff News & Community Trade Idea Sharing - beatles.ru
Should I invest in Syndax Pharmaceuticals Inc. before earnings2025 Top Decliners & Stock Timing and Entry Methods - beatles.ru
Will Syndax Pharmaceuticals Inc. Benefit From Sector TailwindsWatch List & Daily Oversold Stock Bounce Ideas - beatles.ru
Syndax Pharmaceuticals Reports Inducement Grants Under - MSN
When Will Syndax Pharmaceuticals, Inc. (NASDAQ:SNDX) Turn A Profit? - simplywall.st
Trexquant Investment LP Decreases Stock Position in Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Point72 Europe London LLP Acquires Shares of 184,683 Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Wellington Management Group LLP Sells 4,198,493 Shares of Syndax Pharmaceuticals, Inc. $SNDX - MarketBeat
Why is Syndax Pharmaceuticals Inc. stock going downEarnings Growth Summary & Weekly Stock Performance Updates - خودرو بانک
Syndax Pharmaceuticals Inc (SNDX) 財務データ
収益
当期純利益
現金流量
EPS
1.43%
0.09%
大文字化:
|
ボリューム (24 時間):